Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo.
about
Mutations in HIV-1 envelope that enhance entry with the macaque CD4 receptor alter antibody recognition by disrupting quaternary interactions within the trimer.Induction of a Tier-1-like Phenotype in Diverse Tier-2 Isolates by Agents that Guide HIV-1 Env to Perturbation-sensitive, Non-native States.Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways.R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models.A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer.Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo.Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys.Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge.Increased sensitivity to broadly neutralizing antibodies of end-stage disease R5 HIV-1 correlates with evolution in Env glycosylation and charge.The role of the third beta strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence.Molecular evolution of human immunodeficiency virus env in humans and monkeys: similar patterns occur during natural disease progression or rapid virus passage.Turnover of env variable region 1 and 2 genotypes in subjects with late-stage human immunodeficiency virus type 1 infectionBroadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremiaEnvelope variants from women recently infected with clade A human immunodeficiency virus type 1 confer distinct phenotypes that are discerned by competition and neutralization experiments.Vpu Exploits the Cross-Talk between BST2 and the ILT7 Receptor to Suppress Anti-HIV-1 Responses by Plasmacytoid Dendritic Cells.Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.A New Approach to Produce HIV-1 Envelope Trimers: BOTH CLEAVAGE AND PROPER GLYCOSYLATION ARE ESSENTIAL TO GENERATE AUTHENTIC TRIMERSBlockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells.In silico Analysis of HIV-1 Env-gp120 Reveals Structural Bases for Viral Adaptation in Growth-Restrictive Cells.Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response.Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment.The selection of low envelope glycoprotein reactivity to soluble CD4 and cold during simian-human immunodeficiency virus infection of rhesus macaques.Thymic pathogenicity of an HIV-1 envelope is associated with increased CXCR4 binding efficiency and V5-gp41-dependent activity, but not V1/V2-associated CD4 binding efficiency and viral entry.Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization.Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivoProperties of the surface envelope glycoprotein associated with virulence of simian-human immunodeficiency virus SHIV(SF33A) molecular clones.Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same siteInfectivity and neutralization of simian immunodeficiency virus with FLAG epitope insertion in gp120 variable loops.Detailed characterization of antibody responses against HIV-1 group M consensus gp120 in rabbits.Independent evolution of human immunodeficiency virus type 1 env V1/V2 and V4/V5 hypervariable regions during chronic infection.HIV-antibody complexes enhance production of type I interferon by plasmacytoid dendritic cells.Comparison of the genotypic and phenotypic properties of HIV-1 standard subtype B and subtype B/B' env molecular clones derived from infections in China.
P2860
Q30368471-F739F96A-A9F3-4E4C-9D8E-D1557AF95C39Q30401836-A22C4489-EF00-4169-ACF3-5E866B5D7063Q33504599-C000D5BC-F139-48A3-8A3E-7BE0CB3629F5Q33640144-B92E9AE2-8405-4A29-91DA-04784BC53E6CQ33725702-209D1CB1-C9A7-478E-B3BD-406B8E0CE1EDQ33813212-007419DA-5501-41D4-8F59-73DA9D2AAD6EQ33839485-1E419C6F-B78A-4C15-8866-0C020B6A579BQ33843345-3F817DC5-3920-438D-8D51-D1E01A207C56Q33852768-C0138D11-C824-4EB6-AA66-C7C3E6989A1DQ33941033-59DCB46B-0167-4C82-B8A6-9EC3D408D26FQ33953062-B0ECB692-3A87-4CCD-8200-FE418BB3D816Q34016706-A56141D3-60E2-49D2-BCB8-ECEBF87D934DQ34338411-3F04CA29-8936-4E3D-8F48-225C738318DEQ35020053-7F4F0EC3-4975-46C1-9C87-9736E6B6E508Q35077039-3C6FB5E1-2F5A-46ED-842F-C72F1B473B90Q35155451-3229496B-8510-4F68-A73B-1C2F838DF8AEQ35690771-DD049428-CFC0-4855-A1BB-4459D2A6A676Q35785244-D1D6566D-A54D-4436-ACA8-96FA598DDB13Q35925858-84A0C1B0-3F0D-456A-AA66-307A15CD3320Q35973601-1691A543-4E7C-46B2-821A-3A6AE4C0A08DQ36558933-1E6705FC-01CE-4D90-B07C-2C574E282726Q36949880-1B70CE03-4D27-4D27-A113-537F173E8A8FQ37410770-C39F93D2-6EFC-4720-95FD-58073DBE80FAQ37547702-A2346A13-016C-405D-94E0-429A8B9AE9D8Q39242155-A6100F4F-A166-436D-A600-F95726CAF015Q39305772-2EEB146B-2380-4F75-B3E7-8A330E1328C8Q39590956-45CF0410-73BA-4E9C-A6CE-C6DDDAC8E8D8Q39682485-918FFE2D-5163-4CAB-A039-72142E8DB049Q39699375-4746943E-35E3-4DAA-B2F5-5413A488DAD4Q40096483-271AA209-DAE1-4B7F-8B5A-1BAEE5F8672AQ42148035-4EF01678-C817-4A34-A0E9-B495298C7B4DQ42737939-3778FDA0-EF91-42F2-A86D-5092C8D4104EQ47399269-6FC54AC2-44A1-44DD-829F-4D8DD1A32E97Q54209545-DD69CCD7-B2E6-4183-9E35-3B0A944213B3
P2860
Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo.
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Determinants of neutralization ...... ciency virus passaged in vivo.
@ast
Determinants of neutralization ...... ciency virus passaged in vivo.
@en
type
label
Determinants of neutralization ...... ciency virus passaged in vivo.
@ast
Determinants of neutralization ...... ciency virus passaged in vivo.
@en
prefLabel
Determinants of neutralization ...... ciency virus passaged in vivo.
@ast
Determinants of neutralization ...... ciency virus passaged in vivo.
@en
P2093
P2860
P1433
P1476
Determinants of neutralization ...... ciency virus passaged in vivo.
@en
P2093
B Etemad-Moghadam
D Schenten
E K Nicholson
G B Karlsson
P2860
P304
P577
1999-10-01T00:00:00Z